| Events Column |
|
|
| Job Opening:
Lab Tech at Affomix in Branford more |
|
|
| 6/9 6:30 pm - 9:30 pm. LES CT Chapter
Hosts Dan Adams of Protein Sciences. 'Deals That Go South.'
Room TBA, Yale University, New Haven. more |
|
|
|
CURE believes that
relationships between biopharma companies and doctors are
adequately regulated under Federal law and through industry
codes of conduct. Click here
to hear Paul Pescatello's remarks on WNPR. |
|
|
Gutting Tax Incentives And Adding Unnecessary
Regulations Send Wrong Message About State
From the desk of Paul
Pescatello, President and CEO of CURE
 Effective government is about hard choices, not about treating every program the same. We were wise when we established our tax
incentive programs, which are accomplishing the objectives for which they were designed. It would be counterproductive to turn now on the very companies that are investing the most in products, buildings, equipment, and people in our state.
Rather than pulling the plug on programs that work, lawmakers would do well to focus on improving efficiency in state government. That means not only trimming the expense of current governmental operations, but also avoiding unnecessary legislation that adds to the cost of state government
as well as doing business in the state.
For the full story |
|
|
CI Urges Funds Be Retained for Its Programs
Connecticut Innovations (CI), the state’s quasi-public authority responsible for technology investing and innovation development, in an e-mail to state legislators April 22 called on them to defeat a proposal to transfer $9.5 million of funding out of CI.
"Connecticut Innovations invests in emerging technology companies for the purpose of growing the state’s technology economy, creating a technology industry and creating high-quality jobs in
Connecticut," the e-mail stated.
For the
full story
|
|
|
Life Sciences Draw 94% of Q1 CT Venture Capital
Venture capitalists invested
a total off $37.3 million in five Connecticut companies in the
first quarter of 2009, up sharply from $15.1 million in eight
companies in the fourth quarter of 2008, according to The
MoneyTree® Report, issued quarterly by PricewaterhouseCoopers
and the National Venture Capital Association, based on data
from Thomson Reuters.
Of the $37.3 million invested
in the first quarter, $35.2 million, or 94%, represented
investment in life sciences companies (biotechnology and
medical devices).
For the
full story |
|
|
CURE Member News Digest
 454
Life Sciences collaborates with Stanford on hepatitus B
Achillion announces patent grant
Alexion sales for Q1 2009 soar to
$81.3 million
BioRelix renews agreement with
Dalton
Boehringer Ingelheim raises
awareness of TIA/Stroke link
Bristol-Myers Squibb in agreement
with Otsuka
Cantor Colburn climbs in patent
firm ranking
Connecticut Innovations
hosts Annual Technology Celebration
Danbury Hospital accredited as
Chest Pain Center
Genomas inducted into AIMBE
GlaxoSmithKline in agreement with
Pfizer on HIV
Virco Lab
unit of Johnson
& Johnson in pact with SmartGene
Marinus
closes Series B financing
Pfizer to
form two research units after Wyeth acquisition
Protein Sciences considers
swine flu vaccine production
PhRMA
teams
with Families USA
Rib-X
secures patent in China
UConn School of Medicine Dean
Cato Laurencin honored
Yale studies Salmonella 'hijack'
function
For
the full story |
|
